RIKER LAUREN 4
4 · Pacira BioSciences, Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Pacira (PCRX) SVP Finance Lauren Riker Sells Shares
What Happened Lauren Riker, Senior Vice President, Finance at Pacira BioSciences (PCRX), disposed of a total of 6,751 shares in two transactions totaling about $139,746. On 2026-01-30, 2,751 shares were withheld by the issuer to cover tax withholding on vested restricted stock units at $20.54 per share ($56,506). On 2026-02-02, 4,000 shares were sold in the open market under a pre-established Rule 10b5-1 plan at a weighted average price of $20.81 per share ($83,240; sales ranged $20.35–$21.28).
Key Details
- Transaction dates: 2026-01-30 (tax-withholding on RSUs) and 2026-02-02 (open-market sale).
- Prices & values: 2,751 shares @ $20.54 = $56,506; 4,000 shares @ $20.81 (weighted avg; $20.35–$21.28) = $83,240; total ≈ $139,746.
- Footnotes: F1 = shares withheld by issuer for tax withholding on RSU vesting; F2 = open-market sale executed under a Rule 10b5-1 trading plan; F3 = weighted-average price with sales across the stated price range.
- Shares owned after the transactions are not disclosed in the provided filing.
- Filing: Form 4 filed 2026-02-03; timing appears consistent with standard Form 4 deadlines for these transactions.
Context Both actions are dispositions (not purchases). The 2,751-share transaction was a routine tax-withholding related to RSU vesting (common and not necessarily a directional signal). The 4,000-share sale was executed under a previously adopted 10b5-1 plan, indicating the sale was prearranged. For retail investors, purchases generally signal more about insider conviction than routine sales; these transactions appear to be administrative and preplanned.
Insider Transaction Report
- Tax Payment
Common Stock
[F1]2026-01-30$20.54/sh−2,751$56,506→ 56,313.242 total - Sale
Common Stock
[F2][F3]2026-02-02$20.81/sh−4,000$83,240→ 52,313.242 total
Footnotes (3)
- [F1]Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.